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The biochemical and radiological responses to radionuclide
therapy with 177Lu-PSMA-617 targeting prostate-specific
membrane antigen (PSMA) make it a promising approach to
the treatment of patients with metastatic castration-resistant
prostate cancer (mCRPC) [1]. However, PSMA-617 has been
reported to have slower tumour accumulation and clearance
kinetics than PSMA-11, and the latter is still therefore the pre-
ferred diagnostic agent when labelled with generator-produced
68Ga which has a short half-life (68 min) [2]. A PSMA-
targeting 18F-labelled PET tracer could be producedwith higher
activity in a cyclotron and the half-life (110 min) would allow
both late imaging beyond 1 h after injection and shipping to
satellite institutions. However, the structure of the currently
most-used 18F-labelled PSMA tracer, 18F-DCFPyl, is different
from that of PSMA-617, and like PSMA-11 it might be a sub-
optimal surrogate for stratifying patients according to their suit-
ability for therapy with 177Lu-PSMA-617 [3].
Based on the scaffold of PSMA-617, the novel compound
18F-PSMA-1007 was developed. As shown in the image (a, d),
PSMA-1007 shares the Glu-urea-Lys motif targeting the cata-
lytic domain of PSMA and the naphthalene-based linker region
considered to cotarget the hydrophobic accessory pocket [4],
while in the radiolabel-bearing moiety glutamic acids were
added to mimic the carboxylic acid groups of the DOTA che-
lator to retain the polar charge influencing clearance kinetics.
The image also shows a patient with mCRPC who was
staged using 18F-PSMA-1007 (b PET 1 h after injection, max-
imum intensity projection) and treatment with 177Lu-PSMA-
617 (c planar scan 24 h after injection, geometric mean). In
analogy to the chemical structure, the uptake in tumour and
normal organs is very similar with the two compounds.
Thus, 18F-PSMA-1007 and 177Lu-PSMA-617 seem to be a
perfect theragnostic tandem. Due to the preferred physical char-
acteristics of 18F for PET imaging and the possibility for large-
scale production in a cyclotron, 18F-PSMA-1007 is also a prom-
ising alternative to 68Ga-PSMA-11 for diagnostic purposes.
However, non-inferior diagnostic accuracy has still to be proven
in a larger cohort.
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